Is LifeStance Health Group (LFST) overvalued or fairly valued?

MarketChacha shows LifeStance Health Group's valuation in context — a forward P/E of about 28.5, a price-to-book of about 3.2 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is LifeStance Health Group's revenue?

LifeStance Health Group reported revenue of $1.4B for FY2025, with net profit of $9.7M, per official filings.

What is the share price of LifeStance Health Group (LFST)?

LifeStance Health Group last traded at $12.22 (+3.8% on the day), as of 10/20/2026 — a delayed quote shown for education, not investment advice.

LifeStance Health Group

LFST · NYSE · Healthcare · United States

Snapshot

TickerLFST

ExchangeNYSE

SectorHealthcare

IndustryMedical Care Facilities

CountryUnited States

Employees8,542

HeadquartersScottsdale, United States

Websitelifestance.com

Filings tracked16

About LifeStance Health Group

LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a multidisciplinary suite of mental health services, psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It also treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.

Who owns it

Insiders3.1%
Institutions91.3%
Public & other5.6%

412 institutional holders

Ownership breakdown from public market data.

Top holders

TPG GP A, LLC29.24%
FMR, LLC15.24%
Blackrock Inc.9.51%
Summit Partners, L.P.6.10%
Vanguard Portfolio Management LLC3.65%
Jennison Associates LLC3.16%
Dimensional Fund Advisors LP2.99%
Vanguard Capital Management LLC2.55%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Latest ROE of 0.6% is on the low side — the business earns a modest return on shareholder capital.

Net margin trend-17.6% → 0.7%

Margin has expanded by about 18.3 points — the business is getting more profitable.

Return on equity0.6%

Latest ROE of 0.6% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $438.6M · EPS 0.09

Est. earnings growth -2.2%

Next fiscal year

Rev $2.0B · EPS 0.43

Est. earnings growth +19.8%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$1.4B

Net margin

0.7%

ROE

0.6%

Revenue CAGR (2y)

+16.2%

Net profit (FY2025)

$9.7M

Ask MarketChacha about LFST

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin	ROE
FY2025	$1.4B	$9.7M	0.7%	0.6%
FY2024	$1.3B	$-57.4M	-4.6%	-4.0%
FY2023	$1.1B	$-186.3M	-17.6%	-13.0%

Quarterly

Period	Revenue	Net profit	Net margin
2026Q2	$435.4M	$23.6M	5.4%
2026Q1	$403.5M	$14.2M	3.5%
2025Q3	$363.8M	$1.1M	0.3%
2025Q2	$345.3M	$-3.8M	-1.1%
2025Q1	$333.0M	$709,000	0.2%
2024Q3	$312.7M	$709,000	0.2%
2024Q2	$312.3M	$-23.3M	-7.5%
2024Q1	$300.4M	$-21.1M	-7.0%
2023Q3	$262.9M	$-61.6M	-23.4%
2023Q2	$259.6M	$-45.5M	-17.5%
2023Q1	$252.6M	$-34.2M	-13.6%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Reg FD disclosure, Other events, Exhibits
SEC8/6/2026material
10-Q filing
SEC8/6/2026
8-K — Executive/director change
SEC7/7/2026material
8-K — Shareholder vote results
SEC6/4/2026material
8-K — Other events, Exhibits
SEC5/12/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC5/7/2026material
10-Q filing
SEC5/7/2026
8-K — Executive/director change
SEC3/11/2026material
8-K — Other events, Exhibits
SEC3/2/2026material
8-K — Results of operations, Executive/director change, Reg FD disclosure, Other events, Exhibits
SEC2/25/2026material
10-K filing
SEC2/25/2026

2025

8-K — Results of operations, Reg FD disclosure, Exhibits
SEC11/6/2025material
10-Q filing
SEC11/6/2025
8-K — Executive/director change
SEC8/22/2025material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC8/7/2025material
10-Q filing
SEC8/7/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.